Search Results

, hopefully unbiased, fashion. Let’s apply this strategy to two important trials in early-stage breast cancer; the HERA study, which compared 0 versus 1 versus 2 years of trastuzumab as adjuvant therapy for HER2-positive breast cancers (the comparison of 1

landmark studies, such as those that defined adjuvant therapy in breast and colorectal cancers, two of the biggest success stories. So my answer to the title question is “yes,” we need a publicly funded clinical trials network. The pharmaceutical industry

with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix . J Clin Oncol 2000 ; 18 : 1606 – 1613 . 27 Clinical Announcement . National Cancer Institute. Concurrent

those who are initially unresectable, or those with bilateral or metastatic disease. Risk assessment is done to determine the need for and type of adjuvant therapy after surgery (see Risk Assessment for FHWT [WILMS-F] in the algorithm). 10 , 64 Most

has shifted from radical approaches to more conservative surgery with the addition of RT or chemoradiation. 15 Because the data are limited, trials are ongoing to identify optimal approaches for neoadjuvant and adjuvant therapy, which may include

In an era of increasing use of Oncotype DX to assist with chemotherapy treatment decisions, an aging population with comorbidities needing to be addressed, and the more prevalent use of MIR, it is not surprising that wait times to adjuvant therapy

-term survival after pulmonary resection for small cell carcinoma of the lung [comment] . Thorax 1989 ; 44 : 784 – 787 . 11 Shah SS Thompson J Goldstraw P . Results of operation without adjuvant therapy in the treatment of small cell lung cancer

. Lancet 2005 ; 365 : 60 – 62 . 16 Winer EP Hudis C Burstein HJ . American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast

progesterone receptors in the treatment of breast cancer . Cancer 1980 ; 46 ( 12 Suppl ): 2884 – 2888 . 5 Viale G Regan MM Maiorano E . Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of

complete response; TME, total mesorectal excision. Historically, one of the major shortfalls of adjuvant therapy is that many eligible patients, ranging from 17% to 28% in various trials, either do not start postoperative chemotherapy or initiate